Bacteria in your gut can break down your blood pressure pills
For the roughly one in five Americans with hypertension whose medications fail them despite faithful adherence, science has long offered silence where answers were needed. Researchers at the University of Toledo have now turned toward an unlikely suspect — the microbial communities living within us — and found that a common gut bacterium called Coprococcus may be quietly dismantling blood pressure drugs before the body can use them. This discovery, still early and rooted in animal studies, opens a new chapter in understanding how the invisible ecosystems we carry shape the medicines we depend on.
- One in five hypertensive patients cannot control their blood pressure despite medication, leaving them chronically exposed to the risk of heart attack and stroke.
- A bacterium called Coprococcus, found in the gut, appears to chemically break down two widely used blood pressure drugs — quinapril and ramipril — before they can take effect.
- Rats stripped of their gut bacteria responded dramatically better to the same medications, and a human case study showed a woman's resistant hypertension vanished entirely while she was on antibiotics.
- Long-term antibiotic use is not a safe solution, so researchers are now exploring whether probiotics, prebiotics, and dietary shifts could neutralize the offending bacteria without broader harm.
- The National Heart, Lung, and Blood Institute is watching closely, but cautions that human trials are still needed before this mechanism can be confirmed or applied clinically.
Nearly half of American adults live with high blood pressure, and for most of them, medication works. But for roughly one in five, it doesn't — and despite taking their pills faithfully, their blood pressure remains dangerously elevated. Medicine has never had a clear explanation for why.
Researchers at the University of Toledo believe the answer may lie in the gut. A study published in the journal Hypertension found that a bacterium called Coprococcus can chemically break down two common antihypertensive drugs — quinapril and ramipril — before the body has a chance to absorb them. Lead author Dr. Tao Yang described the finding as a potential first step toward understanding and overcoming treatment-resistant hypertension, a condition that quietly raises the risk of heart disease and stroke for millions.
The evidence began with rats. Animals whose gut bacteria had been eliminated with antibiotics responded far better to quinapril than those with normal microbiota. Lab tests then confirmed Coprococcus as the likely culprit. A compelling human parallel emerged from 2015: a woman with a long history of resistant hypertension went on antibiotics for a post-surgical infection and, for two weeks, her blood pressure normalized without any hypertension medication at all. Six months after stopping the antibiotics, her resistance returned.
Because long-term antibiotic use carries serious risks, the research team is looking toward gentler interventions — probiotics, prebiotics, and diet — to selectively suppress the bacteria interfering with treatment. The National Heart, Lung, and Blood Institute, which helped fund the study, called the gut microbiome an understudied frontier in hypertension research, while urging caution until human trials can confirm what animal studies have begun to reveal.
Nearly half of all American adults live with high blood pressure. For most of them, medication works. But for one in five people with hypertension—roughly 20 percent—the drugs simply don't. They take their pills faithfully, follow their doctor's orders, and their blood pressure stays dangerously high anyway. Until now, medicine had no clear answer for why.
A team of researchers at the University of Toledo may have found it hiding in the last place anyone thought to look: the bacteria living in the gut. In a study published this month in the journal Hypertension, scientists discovered that certain bacterial species can chemically break down blood pressure medications before the body has a chance to use them. The culprit is a bacterium called Coprococcus, which appears to metabolize two common antihypertensive drugs—quinapril and ramipril—rendering them less effective at controlling blood pressure.
Dr. Tao Yang, the study's lead author and an assistant professor in the Department of Physiology and Pharmacology at UToledo, framed the stakes plainly. High blood pressure is called a silent killer for a reason: it causes no symptoms, yet it remains one of the leading risk factors for heart disease and stroke in America. For the millions of people who know they have the condition but cannot control it despite medication, the frustration is real and the danger is constant. "Until now, we haven't had any clear indication what the mechanism is for resistant hypertension," Yang said. "Our research could provide a first step toward identifying new ways to effectively overcome treatment-resistant hypertension."
The work began with a straightforward experiment. Researchers compared how well quinapril worked in two groups of rats: one with normal gut bacteria, and another whose microbiota had been wiped out by high-dose antibiotics. The difference was striking. The rats without their normal bacterial populations responded much better to the medication. When the team analyzed the bacterial composition in the untreated animals, they identified Coprococcus as the likely culprit. Laboratory tests confirmed it: this bacterium can break down both quinapril and ramipril, compromising their blood pressure-lowering effects.
The findings remain preliminary—the study was conducted in animals and in the lab, not in living humans. But researchers uncovered a tantalizing case study that suggests the mechanism may apply to people. In 2015, a woman with a long history of treatment-resistant hypertension took antibiotics for a post-surgical infection. For the two weeks she was on antibiotics, her blood pressure normalized without any blood pressure medication at all. After she stopped the antibiotics, it took six months before her hypertension became resistant again. The pattern fits the theory perfectly: eliminate the bacteria, and the drugs work better.
Dr. Bina Joe, chair of UToledo's Department of Physiology and Pharmacology and the study's senior author, emphasized the significance of this line of inquiry. The university has been at the forefront of research linking gut bacteria to hypertension, but Yang's work marks the first time anyone has examined how those bacteria affect medication itself. "This is now a major research theme in his own laboratory at The University of Toledo," Joe said.
The practical implications are substantial. Long-term antibiotic use is not a viable treatment strategy—antibiotics carry their own risks and side effects. But Yang and his team believe it may be possible to alter someone's microbiota through probiotics, prebiotics, and dietary changes. The ultimate goal is to identify which bacteria in an individual's gut are interfering with their medications, then target those specific species to improve drug efficacy. "This has the potential to benefit a lot of people," Yang said.
The research has caught the attention of the National Heart, Lung, and Blood Institute, which provided partial funding. Dr. Young Oh, a program officer at the institute, acknowledged that the study fills an important gap in understanding resistant hypertension. "The gut microbiome has been understudied as it relates to hypertension," Oh said. But he also sounded a note of caution: more research, particularly in humans, will be needed to confirm these findings and understand how broadly they apply. The next phase of work will examine how other blood pressure medications interact with different types of gut bacteria—a landscape that remains largely unmapped.
Notable Quotes
Until now, we haven't had any clear indication what the mechanism is for resistant hypertension. Our research could provide a first step toward identifying new ways to effectively overcome treatment-resistant hypertension.— Dr. Tao Yang, lead author
The gut microbiome has been understudied as it relates to hypertension. While this study fills an important knowledge gap, more studies are needed, particularly in humans, to confirm the findings.— Dr. Young Oh, National Heart, Lung, and Blood Institute
The Hearth Conversation Another angle on the story
So we're saying that bacteria in your gut can actually destroy your blood pressure medicine before it works?
Not destroy it exactly, but metabolize it—break it down chemically into forms your body can't use. It's like the bacteria are eating the drug before your bloodstream gets to it.
And this only happens with certain bacteria? Not everyone's gut bacteria do this?
Right. The study identified Coprococcus as the main culprit. Most people probably have it in their microbiota, but the amount and activity level varies. For some people it's enough to significantly reduce how well the medication works.
If that's true, why hasn't anyone noticed this before?
Because nobody was looking for it. Researchers have studied the link between gut bacteria and blood pressure itself for years, but this is the first time anyone examined whether bacteria could interfere with the medications used to treat it. It's a blind spot in medicine.
Can you just take antibiotics to kill the bacteria and solve the problem?
That's what the case study suggests might work, but no—you can't use antibiotics long-term. They have serious side effects and risks. The real solution would be to use probiotics, prebiotics, or diet changes to shift your microbiota away from the problematic bacteria.
So this could explain why one in five people with high blood pressure can't get it under control?
It could explain some of those cases, yes. Not all of them—resistant hypertension has multiple causes. But this research suggests that for at least some people, their own gut bacteria are working against their medication.